ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,635 | -30.8% | 14,933 | -1.8% | 0.00% | – |
| Q2 2023 | $21,140 | -66.7% | 15,209 | -61.9% | 0.00% | – |
| Q1 2023 | $63,486 | -35.0% | 39,928 | +154.8% | 0.00% | – |
| Q4 2022 | $97,630 | +12.2% | 15,671 | +20.1% | 0.00% | – |
| Q3 2022 | $87,000 | +171.9% | 13,052 | +159.9% | 0.00% | – |
| Q2 2022 | $32,000 | +100.0% | 5,021 | +45.8% | 0.00% | – |
| Q1 2022 | $16,000 | -78.1% | 3,444 | -76.5% | 0.00% | – |
| Q4 2021 | $73,000 | +19.7% | 14,641 | +187.9% | 0.00% | – |
| Q3 2021 | $61,000 | -98.1% | 5,085 | -96.7% | 0.00% | -100.0% |
| Q2 2021 | $3,244,000 | -29.9% | 153,373 | -7.1% | 0.00% | -33.3% |
| Q1 2021 | $4,629,000 | +177.9% | 165,031 | +157.6% | 0.00% | +200.0% |
| Q4 2020 | $1,666,000 | -33.3% | 64,062 | -4.7% | 0.00% | 0.0% |
| Q3 2020 | $2,499,000 | -42.1% | 67,244 | -20.1% | 0.00% | -66.7% |
| Q2 2020 | $4,319,000 | +107.7% | 84,182 | +27.7% | 0.00% | +50.0% |
| Q1 2020 | $2,079,000 | -58.8% | 65,940 | -22.0% | 0.00% | -50.0% |
| Q4 2019 | $5,042,000 | -9.1% | 84,553 | -44.1% | 0.00% | 0.0% |
| Q3 2019 | $5,549,000 | -42.0% | 151,346 | -26.5% | 0.00% | -50.0% |
| Q2 2019 | $9,575,000 | +286.4% | 205,830 | +233.4% | 0.01% | +300.0% |
| Q1 2019 | $2,478,000 | -81.3% | 61,732 | -78.6% | 0.00% | -84.6% |
| Q4 2018 | $13,261,000 | +102.2% | 288,287 | +95.1% | 0.01% | +85.7% |
| Q3 2018 | $6,557,000 | +117.4% | 147,771 | +92.0% | 0.01% | +133.3% |
| Q2 2018 | $3,016,000 | +4.8% | 76,957 | +93.5% | 0.00% | 0.0% |
| Q1 2018 | $2,877,000 | -45.4% | 39,771 | -50.3% | 0.00% | -25.0% |
| Q4 2017 | $5,271,000 | +112.2% | 80,052 | +61.6% | 0.00% | +100.0% |
| Q3 2017 | $2,484,000 | -32.5% | 49,552 | -37.7% | 0.00% | -33.3% |
| Q2 2017 | $3,682,000 | +135.3% | 79,555 | +79.6% | 0.00% | +200.0% |
| Q1 2017 | $1,565,000 | +357.6% | 44,306 | +62.1% | 0.00% | – |
| Q4 2016 | $342,000 | -10.9% | 27,330 | -1.4% | 0.00% | – |
| Q3 2016 | $384,000 | +25.1% | 27,722 | -10.6% | 0.00% | – |
| Q2 2016 | $307,000 | -48.9% | 31,022 | -12.7% | 0.00% | – |
| Q1 2016 | $601,000 | -41.2% | 35,548 | -22.6% | 0.00% | -100.0% |
| Q4 2015 | $1,022,000 | +33.9% | 45,936 | +41.9% | 0.00% | – |
| Q3 2015 | $763,000 | -57.7% | 32,373 | +46.9% | 0.00% | -100.0% |
| Q2 2015 | $1,802,000 | +44.7% | 22,043 | +64.0% | 0.00% | +100.0% |
| Q1 2015 | $1,245,000 | +75.8% | 13,443 | -23.2% | 0.00% | 0.0% |
| Q4 2014 | $708,000 | +49.7% | 17,496 | -9.5% | 0.00% | – |
| Q3 2014 | $473,000 | +56.1% | 19,340 | +1.1% | 0.00% | – |
| Q2 2014 | $303,000 | +6.7% | 19,138 | +2.0% | 0.00% | – |
| Q1 2014 | $284,000 | +7.2% | 18,754 | -2.9% | 0.00% | – |
| Q4 2013 | $265,000 | +32.5% | 19,309 | +82.2% | 0.00% | – |
| Q3 2013 | $200,000 | – | 10,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |